TILs in ER+/HER2- breast cancer
C Criscitiello; A Vingiani; P Maisonneuve; G Viale; G Curigliano
Annals of Oncology, Volume 30, Issue Supplement_3, May 2019, mdz095.004, https://doi.org/10.1093/annonc/mdz095.004
Extract
Background: The role of tumor-infiltrating lymphocytes (TILs) in ER+/HER2- breast cancer (BC) is debated. We evaluated the association of TILs and clinico-pathological (CP) features with distant disease-free survival (DDFS) in a large series of patients (pts) with ER+/HER2- BC.

Methods: A case-cohort was built by randomly selecting 17% of an initial cohort of 3986 pts who underwent surgery at IEO in the period 1998-2002, and for whom long-term follow-up data was available (680 pts). 307 more pts with an event were added to this cohort. TILs were assessed for these 987 cases on centralized H&E slides. TILs were considered both...